IL-6, mouse recombinant
- Known as:
- Interleukin-6, mouse Rec.
- Catalog number:
- bc-280
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Kamiya biomedical company
- Gene target:
- IL-6 mouse recombinant
Related genes to: IL-6, mouse recombinant
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: IL-6, mouse recombinant
Related articles to: IL-6, mouse recombinant
- Crohn's disease (CD) is a chronic inflammatory bowel disease exhibiting substantial heterogeneity in clinical presentation and response to therapy. To explore its molecular basis, we developed IBDverse, a large single-cell RNA sequencing (scRNA-seq) dataset of terminal ileal biopsies, profiling over 1.1 million cells from 111 patients with CD and 232 healthy controls. This resource integrates discovery and replication cohorts for the robust identification of CD-associated cell types, genes and pathways. We uncovered epithelial changes marked by interferon-driven upregulation of major histocompatibility complex class I molecules that persisted in progenitor cells after macroscopic inflammation resolution. ITGA4 macrophages were identified as key inflammatory drivers, showing enriched JAK-STAT signaling and cytokine expression (interleukin-6 (IL-6), IL-12 and IL-23). Heritability analysis linked inflammatory monocytes and macrophages to CD susceptibility, implicating resident and recruited immune cells in pathogenesis. These findings establish a comprehensive cellular and molecular framework for CD, offering insights into disease mechanisms and therapeutic opportunities. - Source: PubMed
Publication date: 2026/06/15
Krzak MonikaAlegbe TobiTaylor D LelandJones Gareth-RhysGhouraba MennatallahStrickland MichelleHarris Bradley TSatti ReemArestang KennethRamirez-Navarro LuciaNishad NilangaCheam Kimberly Ai XianTutert MarcusOzols MatissNoell GuillaumeLeonard StevenPrzybilla Moritz JSuastegui Ciro RamirezKhabirova EleonoraDeng TongNajgebauer HannaPetrova VelislavaJones Carla PWana NoorHu May XueqiSkelton JasonOstermayer JasminGu YongGarri WendyBrezina BiljanaCaballes Charry QueenCorridoni DanieleParkes MilesIyer VivekMartin Cristina CotobalMcIntyre Rebecca ERaine TimAnderson Carl A - Maternal immunisation allows the transfer of protective antibodies to the offspring, reducing the risk of severe infection during early life. While vaccination during pregnancy is clinically recommended, its long-term impact on neurodevelopment remains under investigation. Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by social and behavioural alterations. Here, we evaluated whether prenatal exposure to the COVID-19 mRNA BNT162b2 vaccine or influenza vaccine affects general and autism-related behavioural outcomes in juvenile (4 weeks) and adult (8 weeks) mouse offspring. We also assessed maternal and fetal immune responses by measuring cytokines, soluble P2X7 receptor, BDNF, CRP, and lipid peroxidation in maternal plasma and fetal brain tissue. Prenatal COVID-19 vaccination elicited a moderate maternal cytokine response (increased IL-6 and KC) without overt fetal brain inflammation. Mild, age- and sex-dependent behavioural changes were observed, including anxiety-related parameters in the elevated plus maze and altered locomotion in the open field at 4-8 weeks, however, no consistent or robust ASD-like behavioural phenotype emerged across ages. Fetal P2X7 receptor levels were elevated, while fetal CRP, BDNF, and TBARS remained unchanged. In adult offspring, BDNF was selectively reduced in the prefrontal cortex, whereas hippocampal BDNF and P2X7 receptor levels in both regions were unaffected. Although embryonic P2X7 receptor levels were transiently elevated following COVID-19 vaccination, these changes were not accompanied by fetal inflammation or persistent adult purinergic alterations. Prenatal influenza vaccination induced mild, age-dependent behavioural alterations, such as increased circling in juveniles and reduced sociability in females, without detectable maternal or fetal inflammatory responses or changes in fetal neurotrophic markers. In contrast, maternal poly(I:C) administration provoked robust systemic inflammation and pronounced fetal brain effects, including elevated cytokines, CRP, P2X7 receptor, and region-specific microglial density, accompanied by persistent reductions in adult BDNF expression. Overall, within the limits of this experimental design, prenatal COVID-19 vaccination did not produce long-lasting ASD-like phenotypes or widespread neurodevelopmental alterations, while influenza vaccination had limited and transient effects. These findings are consistent with the absence of widespread or persistent neurodevelopmental disruption in this experimental model, although further studies-including multiple doses, gestational timepoints, and cellular-level analyses-are warranted to fully elucidate mechanisms and long-term outcomes. - Source: PubMed
Publication date: 2026/06/15
Otrokocsi LillaMaácz FruzsinaTod PálGölöncsér FlóraSperlágh Beáta - Clinical data of 3 patients with refractory systemic lupus erythematosus (rSLE) who received chimeric antigen receptor T-cell (CAR-T) therapy at the Department of Rheumatology and Immunology, the First Affiliated Hospital of University of Science and Technology of China, from June to September 2024 was prospectively enrolled. After lymphodepleting preconditioning with cyclophosphamide combined with fludarabine, 2 patients received a low dose (0.5×10⁶/kg) and 1 patient received a medium dose (1.0×10⁶/kg) of a 4th-generation CAR-T cells (SCAR02) targeting cluster of differentiation 19 (CD19) and B-cell maturation antigen (BCMA) and secreting interleukin-6 (IL-6) antibodies. Follow-up was conducted at day 14 and months 1, 2, 3, 6, 9, and 12 post-infusion to systematically evaluate safety (including treatment-related adverse events, cytokines, and immunoglobulin levels) and efficacy (including cellular kinetics, clinical efficacy, and serological markers). All 3 patients were females, aged 37, 25, and 41 years, respectively. During the follow-up period, no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or other serious adverse events occurred. CAR-T cells expanded well in all patients; peripheral blood CD19⁺ B cells were completely depleted on days 9-13 and gradually recovered over 3-5 months. By month 12, the SLE Disease Activity Index 2000 (SLEDAI-2K) scores of patients 1 to 3 decreased from 8, 8, and 9 at baseline to 0, 4, and 0, respectively; anti-double-stranded DNA antibodies all turned negative, and complement levels returned to normal. Two patients achieved drug-free complete remission based on the Definitions of Remission in SLE (DORIS) criteria, and 1 patient achieved an SLE Responder Index-4 (SRI-4) response. This study demonstrates that SCAR02 exhibits a good safety profile and preliminary efficacy in rSLE patients, and its function of secreting IL-6 antibodies may help alleviate CRS. - Source: PubMed
Xu X XWang QZhao X JXiang NHu B LWang X BChen Z - To investigate the effect of exogenous supplementation of umbilical cord blood (UCB) immune cells on immune function reconstruction and hematopoietic function recovery in elderly high-risk myeloid neoplasms (MN) patients. The research includes clinical studies and cell experiments. Clinical data of elderly high-risk MN patients aged >60 years admitted to the Department of Hematology at the Second Hospital of Tianjin Medical University from January 2023 to June 2025 were retrospectively included. Based on treatment regimens, the patients were categorized into chemotherapy group ("3+7"regimen), demethylation therapy (HMA) group (decitabine-based therapy), and UCB group (venetoclax combined with azacitidine plus UCB reinfusion). At 28 days post-treatment, differences were compared among the groups regarding disease remission (complete remission rate), hematopoietic function reconstruction (recovery time of white blood cells and platelets), survival outcomes (overall survival rate and event-free survival rate), and cellular immune function reconstruction [levels of various CD4T cells, CD8T cells, natural killer (NK)cells, etc.]. To further confirm the role of UCB in the bone marrow microenvironment of MN patients, primary bone marrow cells were collected from 3 elderly high-risk MN patients in the UCB group (ileal bone marrow aspiration was performed on day 15 post-treatment and before UCB infusion, with 10 ml of bone marrow aspirated each time); additionally, UCB cells were obtained from 3 healthy donors (sourced from the Shandong Umbilical Cord Blood Hematopoietic Stem Cell Bank of China, all HLA 2/10 matched male donors). Based on different seeding methods of patient primary bone marrow cells and healthy donor UCB mononuclear cells in Transwell chambers, the cells were divided into a control group (patient bone marrow mononuclear cells cultured separately), an indirect co-culture group (non-contact co-culture of patient bone marrow mononuclear cells and UCB cells), and a direct co-culture group (contact co-culture of patient bone marrow mononuclear cells and UCB cells). After 48 hours of culture, the cells from the lower chamber and the supernatant were collected from each group. The proportional differences among immune cell subsets (various T-cell, B-cell, and NK cell subsets) were compared among the three groups, and the differences in cytokine levels among the three groups of the supernatants [tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-6] were also compared. A total of 109 patients were enrolled, including 54 males and 55 females, with an age range [ (, )] of 68 (60, 87) years. There were 38, 39, and 32 cases in the chemotherapy group, HMA group, and UCB group, respectively. Analysis of disease response revealed that the complete response rates in the UCB group [43.8% (14/32) vs 28.2% (11/39), <0.001] and the chemotherapy group [44.7% (17/38) vs 28.2% (11/39), <0.001] were higher than those in the HMA group. In terms of hematopoietic function recovery, the median time to achieve target leukocyte counts in the UCB group was shorter than that in the chemotherapy group [22 (14, 28) vs 28 (24, 37) days, <0.05] and the HMA group [22 (14, 28) vs 31 (21, 42) days, <0.05]. Similarly, the median time to achieve target platelet counts in the UCB group was shorter than that in the chemotherapy group [24 (17, 29) vs 28 (23, 33) days, <0.05] and the HMA group [24 (17, 29) vs 29 (22, 37) days, <0.05]. The survival analysis demonstrated that the 3-year overall survival rate in the UCB group was higher than that in the HMA group (39.1% vs 19.7%, <0.05), while no statistically significant difference was observed compared to the chemotherapy group (>0.05). Similarly, the 3-year event-free survival rate in the UCB group was higher than that in the HMA group (35.8% vs 25.5%, <0.05), with no statistically significant difference compared to the chemotherapy group (>0.05). Regarding the reconstruction of cellular immune function, the proportion of CD4central memory T cells in the UCB group at 28 days post-treatment was lower than that in the chemotherapy group [20% (9%, 29%) vs 32%(23%, 39%), <0.05], while no statistically significant difference was observed compared to the HMA group (>0.05). At 28 days post-treatment, the proportions of CD4naive T cells [45% (30%, 58%) vs 22% (10%, 34%)] and CD8naive T cells [41% (31%, 52%) vs 22% (8%, 36%)] in the UCB group were significantly higher than those in the HMA group (both <0.05), while no statistically significant difference was observed compared to the chemotherapy group (both >0.05). At 28 days post-treatment, the UCB group exhibited higher proportions of CD8effector T cells [40% (33%, 50%) vs 18% (8%, 28%)], CD19B cells [20% (13%, 27%) vs 12% (7%, 14%)], and NK cells [20% (15%, 26%) vs 14% (7%, 21%)] compared to the chemotherapy group (all <0.05). However, the UCB group showed lower proportions of regulatory T cells at 28 days post-treatment than both the chemotherapy group [4% (4%, 6%) vs 7% (7%, 8%), <0.05] and the HMA group [4% (4%, 6%) vs 8% (6%, 12%), <0.05]. In terms of cellular experiments, differential analysis of immune cells revealed that the indirect co-culture group exhibited higher levels of CD8naive T cells, CD4naive T cells, NK cells, and CD19B cell subsets compared to the control group; conversely, the levels of regulatory T cells and CD4central memory T cells were lower than those in the control group (all <0.05). Cytokine level analysis demonstrated that the direct co-culture group showed higher levels of TNF-α and IFN-γ, as well as lower levels of IL-6 compared to the control group (<0.001). Immunocytes such as NK cells in UCB may promote immune function reconstruction and hematopoietic recovery in patients, thereby improving their prognosis. - Source: PubMed
Du C XZhang H QZhang Y HPeng LLuo S QWang YLi Y QTeng G SJiang E LChen BBai J - Ziltivekimab, a monoclonal antibody targeting the interleukin 6 (IL-6) ligand, is being tested in multiple cardiovascular outcome trials. However, because conventional assays for IL-6 cannot distinguish free IL-6 from ziltivekimab-bound IL-6, measured IL-6 levels do not accurately reflect the reduction of biologically active IL-6 among individuals treated with ziltivekimab. Thus, we developed a quantitative model to estimate free IL-6 levels after ziltivekimab treatment. - Source: PubMed
Publication date: 2026/05/28
Nolain PatrickFugger MagnusHellinghus Bibi ToftHilgendorf IngoHøjen Jesper FalkesgaardLibby PeterLiuzzo GiovannaMatter Christian MTuttle Katherine RRidker Paul M